Cumberland files NDA for ifetroban treatment in DMD
The company submitted a rolling FDA application for ifetroban for DMD heart disease, and reported Q3 financial results after closing a strategic $100M transaction.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed